Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer

(2013) Matthew G. Fury et al.   CANCER

Regulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks

(2013) C. Shen et al.   CANCER RESEARCH

IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization

(2013) Addy CM van de Luijtgaarden et al.   Future Oncology

Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies

(2013) Sandra Heskamp et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity

(2012) J. Moroney et al.   CLINICAL CANCER RESEARCH

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study

(2012) Edwin A. Alvarez et al.   GYNECOLOGIC ONCOLOGY

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies

(2011) J. W. Moroney et al.   CLINICAL CANCER RESEARCH

[18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells

(2011) Cathy C. Zhang et al.   CLINICAL CANCER RESEARCH

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies

(2011) E.E.W. Cohen et al.   EUROPEAN JOURNAL OF CANCER

Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors

(2011) Sheri L. Spunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

(2011) Sant P. Chawla et al.   JOURNAL OF CLINICAL ONCOLOGY

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

(2011) Sylvie Négrier et al.   LANCET ONCOLOGY

Updating progress in sarcoma therapy with mTOR inhibitors

(2010) J.- Y. Blay   ANNALS OF ONCOLOGY

Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process

(2010) G. Moriceau et al.   CANCER RESEARCH

Kinases as targets in the treatment of solid tumors

(2010) Georgios Giamas et al.   CELLULAR SIGNALLING

18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model

(2010) N. Aide et al.   JOURNAL OF NUCLEAR MEDICINE

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

(2010) P. J. Houghton et al.   MOLECULAR CANCER THERAPEUTICS

Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

(2009) S. Bielack et al.   ANNALS OF ONCOLOGY

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

(2009) M. Gupta et al.   BLOOD

Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy

(2009) I.M.E. Desar et al.   CANCER TREATMENT REVIEWS

Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts

(2009) A. S. Fung et al.   CLINICAL CANCER RESEARCH

mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis

(2009) Quan Zhou et al.   MEDICAL ONCOLOGY

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development

(2008) Monica Mita et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

(2008) Hung Huynh et al.   JOURNAL OF HEPATOLOGY

Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice

(2008) A. C. M. van d Luijtgaarden   CANCER IMAGING

Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment

(2008) Stefan Sleijfer et al.   Nature clinical practice. Oncology

Initial testing of cisplatin by the pediatric preclinical testing program

(2007) Mimi Tajbakhsh et al.   PEDIATRIC BLOOD & CANCER

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER